Study Link is here - (Originally published in the Journal of Clinical Oncology)
We are grateful to our community of supporters in the PROMISE and PCROWD studies. In these posts, we seek to share insights with you so that you're able to gain greater understanding and use the information in your treatment decisions.
Video - 1:43 Minutes
Dr. Mark Bustoros, of Dana Farber Cancer Institute, provides a brief overview of his research. He identified risk factors that lead to disease progression and the appearance of symptoms in patients diagnosed with Waldenstrom Macroglobulinemia.
The research team developed a classification system to stratify the patients into high, intermediate, or low risk groups that can help identify patients who might benefit from early treatment.